ArticlePloS one2026
Prosthetic joint infection eradication outcomes for DAIR (debridement, antibiotics, and implant retention) procedure according to culture etiology.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsProsthetic joint infection (PJI) is a rare but devastating complication following total hip and knee arthroplasty. While two-stage revision remains the gold standard, debridement, antibiotics, and implant retention (DAIR) offers a less morbid alternative for select patients. The aim of this study was to assess how microbiologic etiology affects DAIR success, with emphasis on fungal, antibiotic-resistant, and culture-negative PJIs, and to identify pathogen-specific predictors that may guide treatment decisions.
methodsA single-center retrospective review was conducted of 173 culture-positive and culture-negative PJIs treated with DAIR between January 2016 and June 2025. Inclusion criteria followed modified Musculoskeletal Infection Society (MSIS) guidelines. Demographics, comorbidities, and microbiologic data were collected. Treatment success was defined as infection eradication without recurrence or need for further surgical intervention, per Delphi consensus. Logistic regression analyses were performed to evaluate associations between treatment success and microbiologic characteristics, as well as between fungal PJI and patient comorbidities.
resultsOverall, infection eradication was achieved in 66.5% of cases. Fungal pathogens were significantly associated with DAIR failure compared to non-fungal organisms (Odds Ratio [OR] 0.06, 95% Confidence Interval [CI] 0.011-0.31, P = 0.001). Culture-negative infections were nearly four times more likely to achieve eradication (OR 3.91, 95% CI 1.43-10.69, P = 0.008). Antibiotic-resistant and gram-positive pathogens were associated with lower success, whereas polymicrobial infections did not differ significantly from single-organism infections (P value = 0.92). Fungal PJIs comprised 8% of cases and exhibited a higher comorbidity burden (median Charlson Comorbidity Index [CCI] 4 vs 2, P = 0.0496).
conclusionsFungal organisms and antibiotic-resistant pathogens were associated with lower rates of infection eradication, underscoring the importance of pathogen-specific risk stratification when considering DAIR. These findings suggest that alternative surgical strategies or heightened surveillance may be warranted in patients with high-risk organisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.